The Total Artificial Heart in End-Stage Congenital Heart Disease

Chet R. Villa* and David L. S. Morales

Cincinnati Children’s Hospital Medical Center, Heart Institute, Cincinnati, OH, USA

The development of durable ventricular assist devices (VADs) has improved mortality rates and quality of life in patients with end stage heart failure. While the use of VADs has increased dramatically in recent years, there is limited experience with VAD implantation in patients with complex congenital heart disease (CHD), despite the fact that the number of patients with end stage CHD has grown due to improvements in surgical and medical care. VAD use has been limited in patients with CHD and end stage heart failure due to anatomic (systemic right ventricle, single ventricle, surgically altered anatomy, valve dysfunction, etc.) and physiologic constraints (diastolic dysfunction). The total artificial heart (TAH), which has right and left sided pumps that can be arranged in a variety of orientations, can accommodate the anatomic variation present in CHD patients. This review provides an overview of the potential use of the TAH in patients with CHD.

Keywords: total artificial heart, congenital heart disease, mechanical circulatory support, pediatrics, bridge to transplantation

BACKGROUND

Ventricular assist devices (VADs) have been shown to improve mortality and quality of life in adults with refractory heart failure. This has led to a dramatic increase in VAD use among adults over the last decade (Kirklin et al., 2014). Recent reports have shown a dramatic increase in VAD use in children as well (Almond et al., 2013; Villa et al., 2017) as ~20% of pediatric patients are bridged to transplant with a VAD in the current era (Dipchand et al., 2014). These trends in VAD utilization have in turn driven improvements in waitlist mortality for both children (Zafar et al., 2015a) and adults (Emin et al., 2013). Despite the improvement in survival and quality of life brought about by improvements in VAD technology, patients with congenital heart disease (CHD) are less likely to receive a VAD while on the waitlist and are more likely to die while awaiting transplantation (Gelow et al., 2013; Zafar et al., 2015a). The need for improved support options for patients with CHD is significant as ~45% of pediatric heart transplant recipients have CHD (Dipchand et al., 2014) and the number of adults with CHD who experience heart failure (Khairy et al., 2010) or require transplant (Lund et al., 2014) is continuing to grow. Historically, VAD use has not been extended to patients with congenital disease due to multiple factors including patient size, anatomic complexity, multi-organ dysfunction (Kiesewetter et al., 2007; Dimopoulos et al., 2008; Ridderbos et al., 2015) and complex physiology including both systolic (Piran et al., 2002) and diastolic dysfunction (Gewillig et al., 1992). Data is starting to be collected regarding the use of VADs in patients with CHD, however, the current literature is limited to single center case series/case reports. This review will discuss the physiology underlying end stage heart disease with a focus on the potential use of the total artificial heart (TAH).
A few proprietary artificial heart devices have been developed including the SynCardia TAH (SynCardia, Tucson, AZ, USA), AbioCor (Abiomed, Danvers, Massachusetts, USA), and CARMAT (Carmat, Velizy, France). The history of these devices and their clinical use has recently been reviewed (Gerosa et al., 2014). Among the devices listed, the SynCardia (TAH) is the only device currently in use. The CARMAT is currently undergoing feasibility studies, however, data has been limited to a handful of patients thus far (Carpentier et al., 2015). There is also no data on the use of the AbioCor (Dowling et al., 2004) or CARMAT in patients with CHD. Given the paucity of data regarding the use of the AbioCor and CARMAT devices, this review will focus on the use of the SynCardia TAH.

The (TAH) was developed for use in adults with end-stage heart failure who had a contraindication to LVAD or biventricular VAD (BiVAD) (Copeland et al., 2004) including valve insufficiency, intractable arrhythmias and ventricular clot. Device use has subsequently been expanded to younger patients (Leprince et al., 2005; Ryan et al., 2015) and patients with CHD (Morales et al., 2012; Kirsch et al., 2013; Rossano et al., 2014; Ryan et al., 2015). The use of the TAH for complex CHD is potentially paradigm shifting for selected patients. Congenital heart patients with end-stage heart failure who have residual lesions (i.e., VSD, severe semilunar valve insufficiency, stenotic right ventricular to pulmonary artery conduit) that would have to be addressed in order to place a VAD or BiVAD clearly have a different mortality and morbidity profile when compared to patients with cardiomyopathy alone (Zafar et al., 2015b). It is in these patients that the TAH may simplify and optimize support rather than placing a VAD or BiVAD with concurrent cardiac procedures (i.e., VSD closure, conduit revision, aortic valve replacement). The current published experience with the TAH in CHD is listed in Table 1. The range of physiologies (single ventricle, two ventricle) and anatomic abnormalities represented shows the potential for the TAH to address multiple anatomic considerations with implantation alone. The TAH also has the ability to markedly improve patient symptoms and end organ dysfunction in anatomies/physiologies where medical management has shown limited or no benefit (i.e., diastolic dysfunction, CHD (Kouatli et al., 1997; Shaddy et al., 2007; van der Bom et al., 2013, etc.) and VAD options are limited (Table 2).

### Table 1: Clinical experience with the total artificial heart (TAH) in patients in congenital heart disease.

| References       | Anatomy                                                                 | Duration of support | Surgical considerations with TAH implantation                      | Outcome                             |
|------------------|-------------------------------------------------------------------------|---------------------|---------------------------------------------------------------------|-------------------------------------|
| Morales et al., 2012 | Dextrocardia, (S,L,L) ccTGA status post Rastelli with severe aortic insufficiency and obstruction of left ventricle-pulmonary artery conduit | 160 days            | Separation of right and left pumps with parallel orientation         | Bridged to transplantation          |
| Rossano et al., 2014 | Pulmonary atresia with intact ventricular septum status post Fontan     | 61 days             | Creation of “neo-right atrium”                                      | Bridged to transplantation          |
| Si et al., 2015 | Dextrocardia, (S,L,L) ccTGA, ventricular septal defect, pulmonary stenosis and Ebsteinoid tricuspid valve status post Senning-Rastelli with severe tricuspid regurgitation | 8 days              | Reversal of Senning                                                | Bridged to transplantation          |

ccTGA, congenitally corrected transposition of the great arteries.
TABLE 2 | Potential indications for total artificial heart (TAH).

Failing congenital heart disease
- Residual anatomic lesions with coexisting cardiac dysfunction
- Fontan (Rossano et al., 2014)
- Systemic right ventricular failure (Morales et al., 2012)
  - Transposition of the great arteries (TGA), status post Mustard or Senning
  - Congenitally corrected transposition of the great arteries (ccTGA)

Alternate clinical scenarios (Copeland et al., 2004)
- Allograft failure
- Biventricular heart failure
- Cardiac tumor
- Chronic right ventricular failure with existing left ventricular assist device
- Intractable arrhythmias
- Active malignancy receiving cardiotoxic therapies
- Restrictive cardiomyopathy
- Ventricular clot

could not be weaned from ECMO and underwent TAH with Senning pathway reversal. He tolerated the procedure well and underwent heart transplant on POD day 8, followed by hospital discharge within a month.

FAILING FONTAN

Much has been written about the long term outcomes of the Fontan circulation including end-organ dysfunction, and its eventual morbidity and mortality. Generally, there is an obligate increase in central venous pressure with passive flow into the lungs and decreased ventricular preload. This is driven by the initial anatomic considerations as well as inefficient flow dynamics (Whitehead et al., 2007), atrial arrhythmias (Khairy et al., 2008; d’Udekem et al., 2014; Quinton et al., 2015), thromboembolism (Khairy et al., 2008), abnormal pulmonary vascular remodeling (Ridderbos et al., 2015) atrioventricular valve dysfunction, relaxation abnormalities and systolic dysfunction (Piran et al., 2002; Eicken et al., 2003). The culmination of these abnormalities leads to a significant burden of end organ dysfunction (Dimopoulos et al., 2008; Rychik et al., 2012; Schumacher et al., 2014) and mortality (Khairy et al., 2008).

The multiple levels of organ and cardiovascular dysfunction that contribute to Fontan failure (Frazier et al., 2005; Morales et al., 2011; d’Udekem et al., 2014) complicate the discussion regarding the choice and potential benefits of mechanical circulatory support in these patients. For example, while a systemic VAD will improve Fontan physiology when the primary abnormality is systemic ventricular dysfunction the situation is more complex when failure is multifactorial, which is more often the case (Khairy et al., 2008). Pulmonary vascular remodeling (Khambadkone et al., 2003; Ridderbos et al., 2015) and diastolic abnormalities (Anderson et al., 2008) often conspire to limit pulmonary blood flow and assessing the contributions of each is difficult at best. One process may also exacerbate the other as cavopulmonary associated power loss may lead to chronic underfilling (Haggerty et al., 2015) and worsening diastolic dysfunction. The degree of diastolic dysfunction may also be underappreciated by testing at rest as Fontan patients may have limited inotropic reserve (Senzaki et al., 2006). A recent report from the Pediatric Heart Network Investigators suggests that while desaturation and inotropic reserve may limit exercise function, impaired stroke volume reserve (Paridon et al., 2008) may be the primary driver of Fontan dysfunction as the inability to increase trans-pulmonary blood flow drives impaired systemic ventricular preload. This is in keeping with data suggesting power loss within the Fontan worsens with activity (Khiabani et al., 2015). Thus, augmenting systemic ventricular output with a VAD alone may not improve the overall physiology and may lead to further increases in central venous pressure as trans-pulmonary blood flow remains the limiting factor.

In addition, the failing Fontan circulation is often addressed as a single state to which different therapies are applied. However, this is a misconception as early Fontan failure is very different than late Fontan failure. Each of these stages of Fontan failure probably require different therapies and applying one therapy to all of the stages will result in inconsistent results. Early failure of the Fontan Circulation is commonly noted by the development of re-entrant tachycardia or mild clinical symptoms. For those patients with an atrial-pulmonary Fontan or anatomic obstruction, this may be successfully addressed with a Fontan conversion. Those patients who start to develop atrial fibrillation and early signs of renal or hepatic dysfunction are in moderate failure and can still be successfully treated with cardiac transplantation (Kanter et al., 2011). There is growing evidence that VAD support can be successful in a subset of these patients (Halaweish et al., 2015; Jabbar et al., 2015), however, it remains unclear when VAD implantation should be considered and what percentage of patients will benefit from systemic VAD alone. Patients with isolated, or predominant ventricular failure, are likely to benefit from VAD alone, however, Fontan failure is commonly multifactorial. A VAD will surely not help the clinical situation if the end-diastolic pressure of the systemic ventricle is not high (at least above 12 mmHG). Some centers have utilized a sub-pulmonary assist device either alone (Prêtre et al., 2008) or as part of a “biventricular” support strategy (Nathan et al., 2006; Valeske et al., 2014) in circumstances where the pulmonary vascular bed remained a limiting factor and CVP remained elevated, however, the results are mixed and the medium to long term outcome of this approach remains unclear. The addition of a sub-pulmonary assist device to force blood through an abnormal pulmonary vascular bed and into an often restricted systemic ventricle in the setting of heart failure is unlikely to be a successful long-term support strategy. On the other hand, the application of a sub-pulmonary support system very early in the clinical course, prior to the development of multi-organ dysfunction, may be able to avoid many of these concerns and is the topic of ongoing research (Di Molfetta et al., 2015). Those patients presenting with severe failure of their Fontan circulation, who have developed marked end-organ dysfunction, protein losing enteropathy, and/or plastic bronchiolitis are not good transplant candidates. It is these patients who may benefit from the TAH as it not only provides a supra-physiological cardiac index (often over 4 L/min/m²) but does so with a low CVP, something rarely
seen with VADs or even early after transplantation. It is this immediate improvement in cardiac output in the environment of a decongested venous system that may allow recovery of renal (Ryan et al., 2015) and liver disease previously thought not to be reversible and thus improve transplant candidacy/mortality (as has been demonstrated in VAD use in adults with end-stage heart failure Russell et al., 2009).

The feasibility of using a TAH in the failing Fontan has been demonstrated in a recent case report by Rossano et al. (2014). The team placed a TAH in a 13 year old with pulmonary atresia with intact ventricular septum who presented in extremis with respiratory failure, hepatic dysfunction, and plastic bronchitis. A 70-cc TAH was placed after creating a “neo-right atrium.” The patient recovered end organ function and was able to ambulate prior to transplantation on POD 61. This case was also significant because it demonstrated the possibility of constructing a capacitance chamber in patients without two adequate AV valves. This is possible because the TAH does not generate significant “suction” which would collapse the capacitance chamber. That said, the mass of the device compressing the neo-atrium is a significant concern and may complicate this support strategy. It remains to be seen if a reproducible and efficient TAH implantation method can be developed that will function for the vast majority of Fontan anatomies.

VIRTUAL FIT

The TAH presents a number of potential advantages to VAD support in patients with congenital abnormalities and with complex hemodynamics, anatomic abnormalities or previous palliations for the reasons mentioned above; however, the implantation is technically more challenging than implantation of a VAD. Assessing thoracic anatomy and device fit has been a concern since the early development of artificial hearts (Jacobs et al., 1978). This issue is particularly relevant in small adults (i.e., women) and adolescents. Historically, the 70 cc TAH was limited to adults or adolescents with a minimum 10 cm distance from the anterior surface of the T10 vertebral body to the sternum in order to ensure device alignment and to prevent kinking or obstruction of venous structures and the outflow grafts. Size based fit recommendations were subsequently developed (Copeland et al., 2004). Population based size and anatomic assumptions regarding chest shape/size, heart size and arterial relationship have given rise to patient specific virtual implantation based on cross sectional imaging (Chatel et al., 1993; Zhang et al., 1999; Dowling et al., 2004; Moore et al., 2014). Understanding patient specific anatomy and device fit is likely to be even more significant in patients with CHD given the range of chamber, valve and great vessel anomalies across the disease spectrum.

SYNCARDIA® 50 CC CLINICAL TRIAL

While virtual fit may expand the number of patients who may benefit from a TAH, there was a clear need for a smaller device to accommodate small adults (especially women) and adolescents who are too small for the 70 cc TAH. Syncardia® has now developed a 50 cc pump which is 30% smaller by volume and is now enrolling children and adults in a bridge to transplant clinical study (Figure 1). The study will have both pediatric (age 10–18 years) and adult (19–75 years) arms. There are also secondary study arms for patients who would not qualify for study inclusion due to ECMO (either V-A or V-V) support >3 days or only 1 functioning AV valve (both of which are relevant to patients with CHD). Importantly, inclusion in the study is not based solely on patient BSA or thoracic measurement in a single plane. Patients can enroll in the study if virtual implantation suggests device implantation is feasible. Preoperative virtual implantation may alter device selection in up to ~33% of patients and may help to identify patients with a BSA ˂1.2 m\(^2\) who are candidates for implantation (Moore et al., 2016).

CONCLUSIONS

The last few decades have seen a dramatic improvement in clinical outcomes among patients with CHD. These improvements are most pronounced in young children and those with severe CHD (Moons et al., 1970; Nieminen et al., 2007; Khairy et al., 2010) which were historically almost uniformly fatal. While early survival and improved quality of life are now the rule, many of the surgical interventions employed for repairing CHD are palliative rather than curative. This has shifted the burden of heart failure and cardiac mortality to the teenage and early adult years (Zomer et al., 2013; Diller et al., 2015). While the availability of VAD technology has improved overall heart failure outcomes, the proportion of patients with CHD who are supported by a VAD noticeably trails the proportion of patients with cardiomyopathy who are supported by a VAD (Davies et al., 2011). This is especially concerning given children (Almond et al., 2009; Jeeva et al., 2014; Zafar et al., 2015a) and adults (Davies et al., 2011) with CHD have higher waitlist mortality. The differences in waitlist mortality are multifactorial, but have been attributed to both limited access to VAD technology (Gelow et al., 2013) and sub-optimal outcomes once a VAD has been implanted in patients with...
CHD (Davies et al., 2011; Everitt et al., 2011). Recent use of the TAH (Morales et al., 2012; Rossano et al., 2014) has highlighted how the TAH may be able to overcome some of the historical limitations to VAD use in CHD, although long-term data is needed. The TAH has the ability to improve end-organ function by simultaneously increasing cardiac output and lowering CVP, to address restrictive heart failure, and to provide a reliable, pulsatile pump that can address the multiple levels of failure that lead to Fontan failure. The TAH pumps may also be placed in a variety of orientations (criss-cross, parallel, other) which allows surgical flexibility and innovation to account for the anatomic variation associated with CHD. Ultimately, these characteristics may make the TAH the most effective bridge to normal physiology for patients with complex CHD who have been only partially medically or surgically palliated since birth.

**AUTHOR CONTRIBUTIONS**

CV provided conception/design of the review, contributed to critical drafting and revision of the manuscript and provided final approval for the manuscript. DM provided conception/design of the review, contributed to critical drafting and revision of the manuscript and provided final approval for the manuscript.

**REFERENCES**

Aguasala, K., Bogaev, R., Frazier, O. H., and Franklin, W. J. (2010). Ventricular assist device placement in an adult with D-transposition of the great arteries with prior Mustard operation. *Congent. Heart Dis.* 5, 635–637. doi: 10.1111/j.1747-9003.2010.00408.x

Almond, C. S., Morales, D. L., Blackstone, E. H., Turrentine, M. W., Imamura, M., and Massicotte, M. P. (2013). Berlin heart EXCOR pediatric ventricular assist device for bridge to heart transplantation in US children. *Circulation* 127, 1702–1711. doi: 10.1161/CIRCULATIONAHA.112.000685

Almond, C. S., Thiagarajan, R. R., Piercey, G. E., Gauvreau, K., Blume, E. D., Bastardi, H. J., et al. (2009). Waiting list mortality among children listed for heart transplantation in the United States. *Circulation* 119, 717–727. doi: 10.1161/CIRCULATIONAHA.108.815712

Anderson, P. A., Sleper, L. A., Mahony, L., Colan, S. D., Atz, A. M., Breitbart, R. E., et al. (2008). Contemporary outcomes after the Fontan procedure: a Pediatric Heart Network multicenter study. *J. Am. Coll. Cardiol.* 52, 85–98. doi: 10.1016/j.jacc.2008.01.074

Carpentier, A., Latrémoille, C., Cholley, B., Smadja, D. M., Rousset, J. C., Boissier, E., et al. (2015). First clinical use of a bioprosthetic total artificial heart: report of two cases. *Lancet* 386, 1556–1563. doi: 10.1016/S0140-6736(15)05116-0

Chatel, D., Martin-Bouyer, Y., Vicaut, E., Bouchoucha, H., Achar, F., Sablayrolles, J. L., et al. (1993). Criteria for anatomical compatibility of the total artificial heart: computerized three-dimensional modeling of the cardiovascular anatomy. *Artif. Organs* 17, 1022–1035. doi: 10.1111/j.1551-5535.1993.tb03185.x

Copeland, J. G., Smith, R. G., Arabia, F. A., Nolan, P. E., Sethi, G. K., Tsau, P. H., et al. (2004). Cardiac replacement with a total artificial heart as a bridge to transplantation. *N. Engl. J. Med.* 351, 859–867. doi: 10.1056/NEJMoa040186

Davies, R. R., Russo, M. J., Yang, J., Quaegebeur, J. M., Mosca, R. S., and Chen, C. Y. (2013). Berlin heart EXCOR pediatric ventricular assist device for bridge to heart transplantation in US children. *Circulation* 127, 1702–1711. doi: 10.1161/CIRCULATIONAHA.112.000685

Eickem, A., Fratz, S., Gutfried, C., Balling, G., Schwaiger, M., Lange, R., et al. (2003). Hearts late after Fontan operation have normal mass, normal volume, and reduced systolic function: a magnetic resonance imaging study. *J. Am. Coll. Cardiol.* 42, 1061–1065. doi: 10.1016/S0735-1097(03)00986-0

Emm, A., Rogers, C. A., Parameshwar, J., Macgowan, G., Taylor, R., Yonan, N., et al. (2013). Trends in long-term mechanical circulatory support for advanced heart failure in the UK. *Eur. J. Heart Fail.* 15, 1185–1193. doi: 10.1093/ejhf/hft127

Everitt, M. D., Donaldson, A. E., Stehlik, J., Kaza, A. K., Budge, D., Alharethi, R., et al. (2011). Would access to device therapies improve transplant outcomes for adults with congenital heart disease? Analysis of the United Network for Organ Sharing (UNOS). *J. Heart Lung Transplant.* 30, 395–401. doi: 10.1016/j.healun.2010.09.008

Frazier, O. H., Gregoric, I. D., and Messner, G. N. (2005). Total circulatory support with an LVAD in an adolescent with a previous Fontan procedure. *Tex. Heart Inst. J.* 32, 402–404.

Gelow, J. M., Song, H. K., Weiss, J. B., Mudd, J. O., and Broberg, C. S. (2013). Organ allocation in adults with congenital heart disease listed for heart transplant: impact of ventricular assist devices. *J. Heart Lung Transplant.* 32, 1059–1064. doi: 10.1016/j.healun.2013.08.003

Gerosa, G., Scuri, S., Iop, L., and Torregrossa, G. (2014). Present and future perspectives on total artificial hearts. *Ann. Cardiothorac. Surg.* 3, 595–602. doi: 10.3978/j.issn.2225-319X.2014.09.05

Gewillig, M., Daenen, W., Aubert, A., and Van der Hauwaert, L. (1992). Abolishment of chronic volume overload. Implications for diastolic function of the systemic ventricle immediately after Fontan repair. *Circulation* 86, II93–II99.

Graham, T. P. Jr., Bernard, Y. D., Mellen, B. G., Celermajer, D., Baumgartner, H., Cetta, F., et al. (2000). Long-term outcome in congenitally corrected transposition of the great arteries: a multi-institutional study. *J. Am. Coll. Cardiol.* 36, 255–261. doi: 10.1016/S0735-1097(00)00682-3

Haggerty, C. M., Whitehead, K. K., Bethel, J., Fogel, M. A., and Yoganathan, A. P. (2015). Relationship of single ventricle filling and preload to total cavopulmonary connection hemodynamics. *Ann. Thorac. Surg.* 99, 911–917. doi: 10.1016/j.athoracsur.2014.10.043

Halawish, I., Ohye, R. G., and Si, M. S. (2015). Berlin heart ventricular assist device as a long-term bridge to transplantation in a Fontan patient with failing single ventricle. *Pediatr. Transplant.* 19, E193–E195. doi: 10.1111/pet.12607

Jabbri, A. A., Franklin, W. J., Simpson, L., Civitello, A. B., Delgado, R. M. III, and Frazier, O. H. (2015). Improved systemic saturation after ventricular assist device implantation in a patient with decompensated dextro-transposition of the great arteries after the Fontan procedure. *Tex. Heart Inst. J.* 42, 40–43. doi: 10.14503/THIJ-13-3374
with a failing Fontan circulation. J. Thorac. Cardiovasc. Surg. 142, e138–e140. doi: 10.1016/j.jtcvs.2011.05.018

Moraes, D. L., Khan, M. S., Gottlieb, E. A., Krishnamurthy, R., Dreyer, W. J., and Adachi, I. (2012). Implantation of total artificial heart in congenital heart disease. Semin. Thorac. Cardiovasc. Surg. 24, 142–143. doi: 10.1053/j.secmcts.2012.04.006

Nathan, M., Baird, C., Fynn-Thompson, F., Almond, C., Thiagarajan, R., Laussen, P., et al. (2006). Successful implantation of a Berlin heart biventricular assist device in a failing single ventricle. J. Thorac. Cardiovasc. Surg. 131, 1407–1408. doi: 10.1016/j.jtcvs.2006.02.015

Nieminen, H. P., Jokinen, E. V., and Saaranen, H. I. (2007). Causes of late deaths after pediatric cardiac surgery: a population-based study. J. Am. Coll. Cardiol. 50, 1263–1271. doi: 10.1016/j.jacc.2007.05.040

Piran, S. M., Mitchell, P. D., Colan, S. D., Williams, R. V., Blaufox, A., Li, J. S., et al. (2008). A cross-sectional study of exercise performance during the first 2 decades of life after the Fontan operation. J. Am. Coll. Cardiol. 52, 99–107. doi: 10.1016/j.jacc.2008.02.081

Peng, E., O’Sullivan, J. J., Griselli, M., Roysam, C., Crossland, D., Chaudhari, M., et al. (2014). Durable ventricular assist device support for failing systemic morphologic right ventricle: early results. Ann. Thorac. Surg. 98, 2122–2129. doi: 10.1016/j.athoracsur.2014.06.054

Piran, S., Veldman, G., Siu, S., Webb, G. D., and Liu, P. P. (2002). Heart failure and ventricular dysfunction in patients with single or systemic right ventricles. Circulation 105, 1189–1194. doi: 10.1161/01.CIR.105.11.1189

Prêtre, R., Hauswalt, A., Bettex, D., and Genoni, M. (2008). Right-sided univentricular cardiac assistance in a failing Fontan circulation. Ann. Thorac. Surg. 86, 1018–1020. doi: 10.1016/j.athoracsur.2008.03.003

Quinton, E., Nightingale, P., Hudsmith, L., Thorne, S., Marshall, H., Clift, P., et al. (2015). Prevalence of atrial tachyarrhythmia in adults after Fontan operation. Heart 101, 1672–1677. doi: 10.1136/heartjnl-2015-307514

Ridderbos, F. J., Wolff, D., Timmer, A., van Melle, J. P., Ebels, T., Dickinson, M. G., et al. (2015). Adverse pulmonary vascular remodeling in the Fontan circulation. J. Heart Lung Transplant. 34, 404–413. doi: 10.1016/j.healun.2015.01.005

Rossano, J. W., Goldberg, D. J., Fuller, S., Ravishankar, C., Montenegro, L. M., and Gaynor, J. W. (2014). Successful use of the total artificial heart in the failing Fontan circulation. Ann. Thorac. Surg. 97, 1438–1440. doi: 10.1016/j.athoracsur.2013.06.120

Russell, S. D., Rogers, J. G., Milano, C. A., Dyke, D. B., Pagani, F. D., Aranda, J. M., et al. (2009). Renal and hepatic function improve in advanced heart failure patients during continuous-flow support with the HeartMate II left ventricular assist device. Circulation 120, 2352–2357. doi: 10.1161/CIRCULATIONAHA.108.814863

Ryan, T. D., Jefferies, J. L., Zafar, F., Lorts, A., and Morales, D. L. (2015). The evolving role of the total artificial heart in the management of end-stage congenital heart disease and adolescents. ASAIO J. 61, S8–14. doi:10.1097/MAT.0000000000001516

Rychik, J., Veldman, G., Rand, E., Russo, P., Rome, J. J., Krok, K., et al. (2012). The precarious state of the liver after a Fontan operation: summary of a multidisciplinary symposium. Pediatr. Cardiol. 33, 1001–1012. doi: 10.1007/s00246-012-0315-7

Schumacher, K. R., Singh, T. P., Kuebler, J., Aprile, K., O’Brien, M., and Blume, E. D. (2014). Risk factors and outcome of Fontan-associated plastic bronchitis: a case-control study. J. Am. Heart Assoc. 3:e000865. doi: 10.1161/JAHA.114.000865

Senzaki, H., Masutani, S., Ishido, H., Taketazu, M., Kobayashi, T., Sasaki, N., et al. (2006). Cardiac rest and reserve function in patients with Fontan circulation. J. Am. Coll. Cardiol. 47, 2528–2535. doi: 10.1016/j.jacc.2006.03.022

Shaddy, R. E., Boucek, M. M., Hsu, D. T., Boucek, R. J., Canter, C. E., Mahony, L., et al. (2007). Carvedilol for children and adolescents with heart failure: a randomized controlled trial. JAMA 298, 1171–1179. doi: 10.1001/jama.298.11.1171

Si, M. S., Pagani, F. D., and Haft, J. W. (2013). Use of the total artificial heart as a bridge to transplant in a 13-year-old with congenitally corrected transposition of the great arteries. J. Thorac. Cardiovasc. Surg. 151, e1–e73. doi: 10.1016/j.jtcvs.2015.11.049

Valek, S., Yererbakan, C., Mueller, M., and Aikintuer, H. (2014). Urgent implantation of the Berlin Heart Excor biventricular assist device as a
total artificial heart in a patient with single ventricle circulation. *J. Thorac. Cardiovasc. Surg.* 147, 1712–1714. doi: 10.1016/j.jtcvs.2014.01.012

van der Bom, T., Winter, M. M., Bouma, B. J., Groenink, M., Vliegen, H. W., Pieper, P. G., et al. (2013). Effect of valsartan on systemic right ventricular function: a double-blind, randomized, placebo-controlled pilot trial. *Circulation* 127, 322–330. doi: 10.1161/CIRCULATIONAHA.112.135392

Vejlstrup, N., Sørensen, K., Mattsson, E., Thilen, U., Kvidal, P., Johansson, B., et al. (2015). Long-term outcome of mustard/senning correction for transposition of the great arteries in Sweden and Denmark. *Circulation* 132, 633–638. doi: 10.1161/CIRCULATIONAHA.114.010770

Villa, C. R., Khan, M. S., Zafar, F., Morales, D. L., and Lorts, A. (2017). United states trends in pediatric ventricular assist implantation as bridge to transplantation. *ASAIO J.* doi: 10.1097/MAT.0000000000000524. [Epub ahead of print].

Whitehead, K. K., Pekkan, K., Kitajima, H. D., Paridon, S. M., Yoganathan, A. P., and Fogel, M. A. (2007). Nonlinear power loss during exercise in single-ventricle patients after the Fontan: insights from computational fluid dynamics. *Circulation* 116, I165–I171. doi: 10.1161/CIRCULATIONAHA.106.680827

Zafar, F., Castleberry, C., Khan, M. S., Mehta, V., Bryant, R., Lorts, A., et al. (2015a). Pediatric heart transplant waiting list mortality in the era of ventricular assist devices. *J. Heart Lung Transplant.* 34, 82–88. doi: 10.1016/j.healun.2014.09.018

Zafar, F., Jefferies, J. L., Tjossem, C. J., Bryant, R. III., Jaquiss, R. D., Wearden, P. D., et al. (2015b). Biventricular Berlin heart EXCOR pediatric use across the united states. *Ann. Thorac. Surg.* 99, 1328–1334. doi: 10.1016/j.athoracsur.2014.09.078

Zhang, B., Masuzawa, T., Tatsumi, E., Taenaka, Y., Uyama, C., Takano, H., et al. (1999). Three-dimensional thoracic modeling for an anatomical compatibility study of the implantable total artificial heart. *Artif. Organs* 23, 229–234. doi: 10.1046/j.1525-1594.1999.06313.x

Zomer, A. C., Vaartjes, L., van der Velde, E. T., de Jong, H. M., Konings, T. C., Wagenaar, L. J., et al. (2013). Heart failure admissions in adults with congenital heart disease; risk factors and prognosis. *Int. J. Cardiol.* 168, 2487–2493. doi: 10.1016/j.ijcard.2013.03.003

**Disclosure:** DM has served as a consultant for Syncardia. DM is also a consultant for HeartWare and Berlin Heart.

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Copyright © 2017 Villa and Morales. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.**